Effects of labetalol combined with low molecular weight heparin on serum PLGF,VEGF levels,and maternal and infant outcome in patients with preeclampsia
Objective To explore the effects of labetalol combined with low molecular weight heparin (LMWH) on serum placental growth factor (PLGF),vascular endothelial growth factor (VEGF) levels,and maternal and infant outcomes in patients with preeclampsia (PE). Methods A total of 80 PE patients admitted to Nanjing Gaochun People's Hospital from March 2020 to October 2023 were randomly divided into three groups:the labetalol group (n=26),the LMWH group (n=27),and the combined group (n=27) treated with labetalol combined with LMWH. The diastolic blood pressure (DBP),systolic blood pressure (SBP),24-hour urinary protein (24 h-PRO),and serum PLGF and VEGF levels were compared be-fore and after treatment. Adverse reactions and maternal and infant outcomes were analyzed. Results After 2 weeks of treatment,SBP,DBP,and 24 h-PRO levels significantly decreased (P<0.05) in all three groups,while serum PLGF and VEGF levels significantly increased (P<0.05). In the combined group,SBPand 24 h-PRO levels were significantly low-er,and serum PLGF and VEGF levels were significantly higher than those in the labetalol and LMWH groups (P<0.05). No significant differences were observed in all indexes between the labetalol group and LMWH group (P>0.05). Adverse reaction rates (14.82％ vs 19.23％ vs 11.11％),maternal adverse outcomes (7.41％ vs 26.92％ vs 11.11％),and neona-tal adverse outcomes (3.70％ vs 15.38％ vs 11.11％) were not significantly different among the three groups (P>0.05). Conclusions Labetalol combined with LMWH shows significant advantages over monotherapy in lowering blood pressure and urinary protein levels,increasing serum PLGF and VEGF levels,and improving maternal and infant outcomes.
万方数据
维普
